Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Printer Friendly Page Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Clinicaltrials.gov identifier:
NCT03981796


Metastatic endometrial cancer

Study Contact Information:

For additional information, please contact: US GSK Clinical Trials Call Center by phone:  877-379-3718 or by email: [email protected]          


Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

About the Study

This study for people with III or IV endometrial cancer will look at how well the combination of the dostarlimab (Jemperli), the niraparib () and chemotherapy works compared with chemotherapy alone. NOTE: This study is no longer enrolling people. 

This Study is Open To:

NOTE: This study is no longer enrolling people. 

This Study is Not Open To:

NOTE: This study is no longer enrolling people.